Simeglutide reclaims the title of global drug king in the second quarter.

According to Novo Nordisk, the company achieved sales revenue of 154.944 billion Danish krone in the first six months of this year, an increase of 16% year-on-year; net profit reached 55.537 billion Danish krone. Among its star products, sales of semaglutide in the first half of the year reached 112.756 billion Danish krone. Specifically, sales of the blood sugar-lowering version of semaglutide injection were 64.52 billion Danish krone, and sales of the weight-reducing version of semaglutide injection were 36.888 billion Danish krone. Converted into US dollars, sales of semaglutide in the first half of this year reached 17.5 billion US dollars. This also means that the sales performance of semaglutide surpassed that of the drug king Palbociclib monoclonal antibody, which is commonly referred to as "K drug".